Merz acquire BioForm Medical

Merz Pharma have agreed to acquire BioForm Medical for $253m, expanding its presence in cosmetic pharmaceuticals

Merz Pharma Group have agreed to acquire BioForm Medical Inc (BFRM) for $253m, expanding its cosmetic pharmaceuticals portfolio. The privately held German pharmaceutical company already has a presence in anti-ageing skincare with their product Belotero - the world's first monophasic hyaluronic acid dermal filler with patented CPM technology.

Merz will pay $5.45 per BioForm share, a 60 per cent premium to the company's Thursday closing price.

BioForm, which went public in late 2007, specialises in injectable drugs to improve the appearance of the skin, including treatment of wrinkles and folds, as well as varicose veins. The company is non profitable, though sales have been improving and last November BioForm narrowed its loss forecast for its fiscal year ending June 30.

6th January 2010

PME Digital Edition

Featured jobs

Head of Partnerships - Competitive - London: Competitive Salary Offered

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior / Principal Medical Writer / ETL - MedComms - HOME BASED ...: D.O.E

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Midweight Brand Planner: Up to £50, 000

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior Medical Writer: Salary TBC

Playing Mind Games: To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists: P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future: As I sit here at another pharma conference, I start to reflect on how they have changed over the years....